An Animated Functional Data Analysis Interface to Cluster Rapid Lung Function Decline and Enhance Center-Level Care in Cystic Fibrosis

Overview

Journal J Healthc Eng

Specialty Biomedical Engineering

Date 2021 Jun 7

PMID 34094041

Citations 1

Authors

Jesse Pratt

Weiji Su

Don Hayes Jr

John P Clancy

Rhonda D Szczesniak

Affiliations

Soon will be listed here.

Abstract

Identifying disease progression through enhanced decision support tools is key to chronic management in cystic fibrosis at both the patient and care center level. Rapid decline in lung function relative to patient level and center norms is an important predictor of outcomes. Our objectives were to construct and utilize center-level classification of rapid decliners to develop an animated dashboard for comparisons within patients over time, multiple patients within centers, or between centers. A functional data analysis technique known as functional principal components analysis was applied to lung function trajectories from 18,387 patients across 247 accredited centers followed through the United States Cystic Fibrosis Foundation Patient Registry, in order to cluster patients into rapid decline phenotypes. Smaller centers (<30 patients) had older patients with lower baseline lung function and less severe rates of decline and had maximal decline later, compared to medium (30-150 patients) or large (>150 patients) centers. Small centers also had the lowest prevalence of early rapid decliners (17.7%, versus 24% and 25.7% for medium and large centers, resp.). The animated functional data analysis dashboard illustrated clustering and center-specific summaries of the rapid decline phenotypes. Clinical scenarios and utility of the center-level functional principal components analysis (FPCA) approach are considered and discussed.

Citing Articles

Predefined and data driven CT densitometric features predict critical illness and hospital length of stay in COVID-19 patients.

Shalmon T, Salazar P, Horie M, Hanneman K, Pakkal M, Anwari V Sci Rep. 2022; 12(1):8143.

PMID: 35581369 PMC: 9114017. DOI: 10.1038/s41598-022-12311-4.

References

Hoo Z, Campbell M, Curley R, Walters S, Wildman M . Do cystic fibrosis centres with the lowest FEV still use the least amount of intravenous antibiotics? A registry-based comparison of intravenous antibiotic use among adult CF centres in the UK. J Cyst Fibros. 2017; 17(3):360-367. DOI: 10.1016/j.jcf.2017.10.005. View

Sanders D, Bittner R, Rosenfeld M, Hoffman L, Redding G, Goss C . Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010; 182(5):627-32. PMC: 5450763. DOI: 10.1164/rccm.200909-1421OC. View

Barrett J, Huille R, Parker R, Yano Y, Griswold M . Estimating the association between blood pressure variability and cardiovascular disease: An application using the ARIC Study. Stat Med. 2018; 38(10):1855-1868. PMC: 6445736. DOI: 10.1002/sim.8074. View

Vandenbranden S, McMullen A, Schechter M, Pasta D, Michaelis R, Konstan M . Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatr Pulmonol. 2012; 47(2):135-43. PMC: 4219484. DOI: 10.1002/ppul.21526. View

Sabadosa K, Godfrey M, Marshall B . Trans-Atlantic collaboration: applying lessons learned from the US CF Foundation quality improvement initiative. Orphanet J Rare Dis. 2018; 13(Suppl 1):13. PMC: 6225611. DOI: 10.1186/s13023-017-0744-8. View

Knapp E, Fink A, Goss C, Sewall A, Ostrenga J, Dowd C . The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry. Ann Am Thorac Soc. 2016; 13(7):1173-9. DOI: 10.1513/AnnalsATS.201511-781OC. View

McPhail G, Weiland J, Acton J, Ednick M, Chima A, VanDyke R . Improving evidence-based care in cystic fibrosis through quality improvement. Arch Pediatr Adolesc Med. 2010; 164(10):957-60. DOI: 10.1001/archpediatrics.2010.178. View

Keogh R, Szczesniak R, Taylor-Robinson D, Bilton D . Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. J Cyst Fibros. 2018; 17(2):218-227. PMC: 5885983. DOI: 10.1016/j.jcf.2017.11.019. View

Szczesniak R, Li D, Duan L, Altaye M, Miodovnik M, Khoury J . Longitudinal Patterns of Glycemic Control and Blood Pressure in Pregnant Women with Type 1 Diabetes Mellitus: Phenotypes from Functional Data Analysis. Am J Perinatol. 2016; 33(13):1282-1290. PMC: 5294951. DOI: 10.1055/s-0036-1586507. View

10.

Dasenbrook E, Merlo C, Diener-West M, Lechtzin N, Boyle M . Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008; 178(8):814-21. DOI: 10.1164/rccm.200802-327OC. View

11.

VanDevanter D, Heltshe S, Spahr J, Beckett V, Daines C, Dasenbrook E . Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis. J Cyst Fibros. 2017; 16(5):607-615. PMC: 6581041. DOI: 10.1016/j.jcf.2017.04.004. View

12.

Froslie K, Roislien J, Qvigstad E, Godang K, Bollerslev J, Voldner N . Shape information from glucose curves: functional data analysis compared with traditional summary measures. BMC Med Res Methodol. 2013; 13:6. PMC: 3570313. DOI: 10.1186/1471-2288-13-6. View

13.

Andrinopoulou E, Clancy J, Szczesniak R . Multivariate joint modeling to identify markers of growth and lung function decline that predict cystic fibrosis pulmonary exacerbation onset. BMC Pulm Med. 2020; 20(1):142. PMC: 7236487. DOI: 10.1186/s12890-020-1177-z. View

14.

Keating D, Marigowda G, Burr L, Daines C, Mall M, McKone E . VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018; 379(17):1612-1620. PMC: 6289290. DOI: 10.1056/NEJMoa1807120. View

15.

Szczesniak R, Brokamp C, Su W, McPhail G, Pestian J, Clancy J . Improving Detection of Rapid Cystic Fibrosis Disease Progression-Early Translation of a Predictive Algorithm Into a Point-of-Care Tool. IEEE J Transl Eng Health Med. 2019; 7:2800108. PMC: 6368437. DOI: 10.1109/JTEHM.2018.2878534. View

16.

Morgan W, VanDevanter D, Pasta D, Foreman A, Wagener J, Konstan M . Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. J Pediatr. 2015; 169:116-21.e2. DOI: 10.1016/j.jpeds.2015.08.042. View

17.

Neuhaus J, McCulloch C, Boylan R . Analysis of longitudinal data from outcome-dependent visit processes: Failure of proposed methods in realistic settings and potential improvements. Stat Med. 2018; 37(29):4457-4471. DOI: 10.1002/sim.7932. View

18.

Kraynack N, David Gothard M, Falletta L, McBride J . Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol. 2011; 46(9):870-81. DOI: 10.1002/ppul.21442. View

19.

Szczesniak R, Li D, Su W, Brokamp C, Pestian J, Seid M . Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood. Am J Respir Crit Care Med. 2017; 196(4):471-478. PMC: 5564675. DOI: 10.1164/rccm.201612-2574OC. View

20.

Szczesniak R, Heltshe S, Stanojevic S, Mayer-Hamblett N . Use of FEV in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher. J Cyst Fibros. 2017; 16(3):318-326. PMC: 5420487. DOI: 10.1016/j.jcf.2017.01.002. View